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Dendritic cells (DCs) are the antigen presenting cells that initiate and regulate immunity. By studying these
cells in vivo, we will be able to move beyond standard approaches and design vaccines that directly harness
the elaborate properties of DCs to control immunity.‘‘The challenge for us as immunolo-
gists is to understand how the
various elements work and fit to-
gether, and then to develop innova-
tive solutions that do better than
nature.. Immunity ranks with the
most complex of complex systems,
along with neurobiology and cli-
mate change.’’ P.C. Doherty and
S.J. Turner, Immunity 27: 363–365
The traditional vaccines that we know
induce immunity against specific micro-
bial antigens and prevent infectious dis-
eases. These vaccines are a major suc-
cess story and emanate in large part
from the discoveries of Louis Pasteur.
His first vaccine against chicken cholera
was created in 1879, and his most famous
vaccine against human rabies was cre-
ated in 1885 (Dubos, 1988). Pasteur’s
research was based on the science of
microbiology, i.e., his discovery that dis-
tinct microbes are the causes of disease
and that an attenuated microbe can in-
duce long-lived protection against infec-
tion by the nonattenuated form of that or-
ganism. These breakthroughs occurred
before there was any clear understanding
of vaccine immunity, which began with
the discovery of antibodies by von Behr-
ing and Kitasato in the 1890s. After the
great advances in immunology during
the twentieth century, a new vaccine era
has finally arrived on the basis of key im-
mune principles.
Vaccines can be defined as formula-
tions that induce specific, nontoxic, and
long-lasting immune responses to pre-
vent or treat disease. The new vaccines
that immunological research can now de-
velop will deliver the relevant antigens and
adjuvants (substances that work with an-tigens to either enhance or silence immu-
nity) to redirect the immune system for
the individual’s benefit (Pulendran and
Ahmed, 2006) (Figure 1). The dendritic
cell (DC) biology that is described in this
issue of Immunity provides a foundation
on which to create vaccines that not only
induce protection against microbes but
also deal with cancer (see Melief, 2008),
autoimmunity, and allergy (see Belkaid
and Oldenhove, 2008).
Here, I will discuss four features of DCs
that establish their central role in develop-
ing new vaccine strategies: location, anti-
gen handling, maturation, and subsets. As
Doherty and Turner write in the introduc-
tory quotation, vaccine biology compels
us to pull these features of DCs together
and ‘‘develop innovative solutions that
do better than nature.’’
Location of Dendritic Cells
In the past, emphasis has been placed on
the capacity of DCs to pick up antigens in
the periphery, including vaccines at an in-
jection site, and then migrate from periph-
eral tissues to the T cell areas of lymphoid
organs to initiate immunity. The underly-
ing biology is elegant (see Alvarez et al.,
2008, this issue), yet more information is
needed on the types of DCs that pick up
vaccine antigens at an injection site,
such as skin or muscle, and initiate immu-
nity. Now additional origins of DCs are ap-
parent (Shortman and Naik, 2007) (see
Lo´pez-Bravo and Ardavı´n, 2008, this is-
sue). In the steady state, most DCs in lym-
phoid organs actually arise from a blood
precursor (Fogg et al., 2006; Liu et al.,
2007). These precursors can proliferate
in the lymphoid organ, a process driven
by flt-3 ligand (Waskow et al., 2008). An-
other potentially major source of DCs isImmunity 29, Smonocytes. Monocyte-derived DCs ac-
cumulate in lymphoid tissues during
some infections, e.g., Leishmania major
(Leon et al., 2007). Learning how to mobi-
lize and access these other reservoirs of
DCs in vivo could enhance the quality
and efficacy of vaccine-induced immu-
nity.
Effective mucosal immunity or resis-
tance at body surfaces is a major hurdle
for vaccine development, probably be-
cause mucosal surfaces are specialized
to sustain nonreactivity to all the innocu-
ous antigens within commensal microor-
ganisms and the proteins in the air we
breathe and the foods we eat. HIV-1 vac-
cines for example will probably need to
induce mucosal immunity because this
virus is most often transmitted via a
mucosal route and quickly leads to a
rapid loss of T cells in the intestine
(Brenchley et al., 2004; Mehandru et al.,
2004). DCs are uniquely located beneath
the epithelium at several mucosal sur-
faces, such as the airway, intestine, and
stomach. Intravital microscopy has
helped reveal that these cells insinuate
their dendritic processes between epithe-
lial cells to enter the mucosal lumen
(Chieppa et al., 2006; Niess et al., 2005).
A critical goal is to determine whether
vaccines can be designed to access
these mucosal DCs to bring about better
mucosal immunity. Depending upon the
medical condition under investigation,
desirable mucosal vaccines need to in-
duce both antibodies and T cells that
block infection at the site of pathogen en-
try, or alternatively activate suppressor
T cells (‘‘regulatory T cells’’), which have
the potential to block the inflammatory
and allergic diseases at mucosal surfaces
(see Belkaid, 2008). One gap in currenteptember 19, 2008 ª2008 Elsevier Inc. 319
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and adjuvant delivery to DCs
associated with organized
mucosal lymphoid tissues
such as Peyer’s patches. Be-
cause the latter are covered
by a distinctive epithelium
rich in antigen-transporting
M cells, receptors on these
M cells, if ligated, could im-
prove vaccine delivery to the
DCs that lie underneath (No-
chi et al., 2007).
A hallmark of DC location is
their abundance in lymphoid
tissues, particularly the T cell
areas (Alvarez et al., 2008).
Numerically, DCs represent
a tiny fraction of total cells,
but their processes con-
stantly probe the environ-
ment, forming a vast and labyrinthine net-
work through which lymphocytes must
pass (Lindquist et al., 2004). This sets
the stage for the selection of rare but spe-
cific clones of lymphocytes during the ini-
tial steps of vaccination. It is now feasible
to target vaccine antigens directly to
these numerous DCs in the T cell areas
and modulate their function with adju-
vants (Bonifaz et al., 2004; Boscardin
et al., 2006; Trumpfheller et al., 2008;
Trumpfheller et al., 2006).
Antigen Handling by Dendritic Cells
Because of the molecular identification of
the DEC-205 (CD205) antigen uptake re-
ceptor on DCs (Jiang et al., 1995), it has
become apparent that these cells express
a plethora of such receptors, often lectins.
These molecules deliver antigens to pro-
cessing compartments, leading to the
presentation of antigen fragments on
MHC and CD1 molecules (see Villadan-
gos and Young, 2008). Endocytic recep-
tors in some cases also signal DC activa-
tion or deactivation (Robinson et al.,
2006). Although DCs are able to capture
antigens as solutes in endocytic vacuoles
(‘‘pinocytosis’’), the identification of up-
take receptors changes the study of DC
biology in vivo and opens new possibili-
ties for efficient vaccine delivery to DCs
and vaccine design.
By identifying specific ligands for anti-
gen uptake receptors on DCs, or by using
monoclonal anti-receptor antibodies as
surrogate ligands, one can efficiently tar-
get vaccine antigens to DCs or their sub-
sets (see below) in vivo (Hawiger et al.,
2001). Retroviral vectors gain improved
immunogenicity if the envelope is engi-
neered to target the DC-SIGN (CD209)
receptor on DCs (Yang et al., 2008). The
efficacy of HIV DNA vaccines can be im-
proved by targeting to DEC-205 (Nchinda
et al., 2008). Low doses of protein-based
vaccines have also been targeted to
DEC-205 along with poly IC as adjuvant.
This leads to a large T helper 1 (Th1) cell
type of T cell response, whereas targeting
to the DCIR2 receptor on another subset
of DCs allows both IFN-g and IL-4 to be
induced (Soares et al., 2007; Trumpfheller
et al., 2008). Receptor targeting not only
enhances antigen uptake and processing
a hundred fold but also facilitates re-
search on DCs and receptor function
in vivo without the need to isolate the
cells (Hawiger et al., 2001)(Bonifaz et al.,
2004).
Another major hurdle for vaccine design
is ‘‘crosspresentation.’’ Nonreplicating
vaccines, e.g., the Salk inactivated viral
vaccine, as well as protein vaccines,
e.g., the diphtheria-pertussis-tetanus
(DPT) vaccine, are capable of inducing
antibody and CD4+ T cell immunity, suffi-
cient in quantity and quality to provide
protection against the polio virus and
DPT toxins, respectively. However, in or-
der for protein-based vaccines to elicit re-
sistance to HIV and cancer, a nonreplicat-
ing form of an antigen needs to elicit
MHC-class-I-restricted, CD8+ or cyto-
toxic T cells. Typically, MHC I presenta-
tion requires microbial replication and an-
tigen synthesis in an infected
cell; e.g., attenuated viral
vectors can elicit CD8+ cyto-
toxic T cells, but they also
elicit antivector immunity
that can compromise the effi-
cacy of booster doses of
vaccine. Crosspresentation
could overcome these hur-
dles because it provides
a route for ‘‘exogenous’’ vac-
cine proteins to be processed
and to gain access to MHC I.
Mechanisms are under study
(Kasturi and Pulendran,
2008); the latest concept is




et al., 2008; Di Pucchio
et al., 2008). Certain receptors may be
specialized to traverse the crosspresen-
tation pathway, such as Fc receptors for
antibody complexes (Dhodapkar et al.,
2002a; Regnault et al., 1999), receptors
for dying cells (den Haan et al., 2000; Dho-
dapkar et al., 2002b; Iyoda et al., 2002),
and certain C-type lectin receptors such
as DEC-205 (Bonifaz et al., 2004; Boz-
zacco et al., 2007). Targeting these recep-
tors with vaccines may help to overcome
the crosspresentation hurdle during vac-
cination. Nonetheless, I urge the field to
move beyond the dominant use of ovalbu-
min in C57Bl/6 mice as the model antigen
for these studies because it is orders of
magnitude more sensitive than the anti-
gens that need to be crosspresented to
create effective vaccines. Ovalbumin
may be distorting the standards for dis-
covering safe, defined, protein-based
vaccines.
Maturation of Dendritic Cells
The most intricate feature of DCs is their
capacity to differentiate or mature along
many different lines. This is driven by
many different types of stimuli including
(1) microbial ligands for pattern recogni-
tion receptors, (2) innate lymphocytes,
(3) immune complexes acting on Fc re-
ceptors, and (4) additional environmental
and endogenous stimuli termed ‘‘alar-
mins.’’ Maturing DCs, depending on the
stimulus as well as environmental factors
affecting lymphocytes, then determine
the type of response, which can be either
immunogenic, providing resistance, or
Figure 1. Some Key Challenges for Vaccines in Immunological
Science and Medicine320 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.
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sponse. One sphere of immunity that is
particularly sensitive to the type of stimu-
lus encountered by DCs is CD4+ helper
T cell differentiation. The specific pathway
followed by CD4+ T cells, whether it in-
volves Th1, Th2, Th17, Tf, Tr1, or Treg
cell differentiation, is significantly gov-
erned by DCs.
A major challenge is to understand how
vaccine adjuvants influence DC matura-
tion in vivo, so that the resulting immunity
will appropriately resist a particular patho-
gen or disease. Two important areas of
science are pattern recognition receptors
and DC subsets (next) (Agrawal et al.,
2003; Shah et al., 2003). Synthetic dou-
ble-stranded RNA, poly IC, is recognized
by TLR3 and MDA-5 receptors, and it
can polarize CD4+ T cells along a Th1
cell pathway when delivered with antigens
to the CD205+ DC subset (Soares et al.,
2007; Trumpfheller et al., 2008). TLR7-
TLR8 and TLR9 ligands also can serve
as adjuvants for responses by IFN-g-pro-
ducing T cells (Wille-Reece et al., 2006). In
contrast, ligands for the dectin receptor,
when applied to bone-marrow-derived
DCs, lead to IL-2 and IL-10 production
and seem to favor Th17 cell differentiation
(LeibundGut-Landmann et al., 2007). Li-
gation of c-kit and TSLP receptors allows
DCs to induce Th2 cell responses, a pro-
cess that takes place in the presence of
certain allergens such as the house
dust-mite allergen (Krishnamoorthy
et al., 2008; Soumelis et al., 2002). These
observations set the stage to design vac-
cines that direct the antigen-presenting
DCs and/or the responding T cells to de-
velop selected types of immunity; e.g.,
Th1 T cells help resist many viruses and
tumors, Th2 cells mediate parasitic infec-
tions, and Th17 cells respond to certain
extracellular bacteria and fungi.
An exciting new area will be to design
vaccines to specifically silence unwanted
immune reactions by taking advantage of
DC programs that lead to tolerance. DCs
can induce tolerance by deleting or si-
lencing T cells (Brimnes et al., 2003; Ha-
wiger et al., 2004), but they can also in-
duce differentiation of suppressive T cells,
e.g., IL-10 producers (Levings et al., 2005;
Macdonald et al., 2005), and foxp3+ Treg
cells (Kretschmer et al., 2005; Luo et al.,
2007). Environmental cytokines such as
IL-10 and TGF-b, as well as vitamin A,
can be critical. The CD8+ or CD205+ sub-set of DCs in mice produces more TGF-
b (Wang et al., 2008; our unpublished
data) and also metabolizes vitamin A to
retinoic acid; TGF-b and retinoic acid are
cofactors for Treg cell development
(Coombes et al., 2007; Sun et al., 2007).
A different pathway involves the E-cad-
herin that DCs use to bind other cells or
other DCs; when the DCs detach, the
E-cadherin signals upregulation of the
lymph-node-homing receptor CCR7 and
production of tolerizing amounts of IL-10
(Jiang et al., 2007). In yet another route
(and there will be many others!), ligation
of select ILT molecules on DCs makes
them tolerogenic (Liang et al., 2008; Man-
avalan et al., 2003). For these reasons, we
can start to think about designing vac-
cines that harness antigen-presenting
DCs to regulate and suppress specific,
undesirable immune responses in allergy,
autoimmunity, and transplantation.
Subsets of Dendritic Cells
Certain markers divide DCs into distinct
forms termed subsets (Villadangos and
Young, 2008). Many of these markers
are receptors involved in pattern recogni-
tion and antigen presentation, the key
steps in innate and adaptive immunity.
All subsets, however, can share charac-
teristic features of the DC lineage such
as an unusual, probing dendritic morphol-
ogy, high amounts of MHC class II, and
potent T cell-stimulating activity.
DC subsets are likely to be selected to
recognize distinct pathogens or forms of
antigen and then follow through with dis-
tinct innate and adaptive responses (Liu,
2005; Shortman and Naik, 2007). To illus-
trate, plasmacytoid DCs express Toll-like
receptors (TLR7, TLR8, and TLR9) and re-
spond to viral and self-nucleic acids with
vigorous type I interferon production (Ka-
dowaki et al., 2000) (Boonstra et al., 2003)
(Boule et al., 2004) (Lande et al., 2007); the
plasmacytoid subset also has special en-
dosomal compartments for crosspresen-
tation on MHC I (Di Pucchio et al., 2008).
Another subset of CD205+ ‘‘myeloid’’
DCs seems specialized to take up and
crosspresent antigens from dying cells
(den Haan et al., 2000; Iyoda et al.,
2002). Within the skin, there are DC sub-
sets that are specialized to induce either
cytotoxic T cells or antibody-forming B
cells (Klechevsky et al., 2008, this issue).
In all these instances, it is likely that the
immunogenic DC subset, and conceiv-Immunity 29, Sably a tolerogenic DC subset as well,
must present the relevant vaccine antigen
and directly respond to the vaccine adju-
vant (Sporri and Reis e Sousa, 2005;
Sporri and Reis e Sousa, 2003). DC sub-
sets therefore greatly expand the number
of targets that vaccines can exploit to
control immunity.
Monocyte-derived DCs comprise an-
other type of DC subset(s). The term is
used in two contexts and their relationship
is still not established. In vivo, monocyte-
derived DCs were recently described in
lymph nodes during infection of mice
with the parasite L. major (Leon et al.,
2007; see Lo´pez-Bravo and Ardavı´n,
2008), but their functional properties rela-
tive to other DC subsets in lymphoid tis-
sues remain undefined. In addition, for
many years scientists have been stimulat-
ing monocytes in vitro to develop many
features of DCs (Romani et al., 1994; Sal-
lusto and Lanzavecchia, 1994). Human
monocyte-derived DCs are notably plas-
tic depending upon the type of cytokines
in the culture, e.g., IL-4, IL-15, or type I in-
terferon (Dubsky et al., 2007). It still needs
to be determined whether a vaccine ap-
proach based on monocyte-derived DCs
can influence the immune outcome.
DC subsets can vary from one another
in all the other features described above:
location, receptors, and maturation pro-
grams. Nonetheless, given the potential
importance of DC-subset diversity in de-
termining the outcome of immunization,
particularly the need to generate CD8+ cy-
totoxic T cell immunity in cancer and in-
fections like AIDS, it is unsettling that the
information base for DC subsets, includ-
ing pattern-recognition receptors, is scant
for DCs in intact human lymphoid and
mucosal tissues.
An Exciting but Challenging Time
for Vaccine Science
It is widely acknowledged that fundamen-
tal discoveries are needed to develop new
vaccines (Klausner et al., 2003). Vaccine
science will identify and understand the
antigens, adjuvants, and protective cells
that provide specific, durable, and non-
toxic therapies. In the case of AIDS vac-
cines, discovery-dedicated academic
scientists are finally beginning to receive
the support and coordination they require,
particularly through the new initiatives of
the Bill and Melinda Gates Foundation
and the National Institute of Allergy andeptember 19, 2008 ª2008 Elsevier Inc. 321
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same cannot be said for other disease
targets, particularly cancer. Immunologic
approaches to cancer have proven to be
effective especially with monoclonal anti-
bodies. However, cellular- and vaccine-
based therapies remain underappreciated
and poorly supported areas of research,
either as stand-alone approaches or in
combination with other therapies (see Me-
lief, 2008). Cancer patients also illustrate
most poignantly the difficulties with the
currently prevailing therapies against dis-
eases that interact with the immune sys-
tem. These drugs can have toxic and ‘‘off-
target’’ side effects and typically require
frequent use. Vaccines, in contrast, offer
the ultimate ‘‘targeted’’ therapy because
they have the capacity to reach many spe-
cific targets in tandem, such as the many
alterations in cancer cells, and because
they remain directed and durable in their
effects.
Vaccine design is often considered an
empirical activity. But let us not be de-
railed by the ‘‘empirical’’ or ‘‘descriptive’’
label. The fundamental challenges are sci-
entific, in that we must discover disease-
relevant antigens, adjuvants, and protec-
tive mechanisms. Immunology is ready
to address these challenges to under-
stand how the various elements work
and fit together. This is because the im-
mune system deals directly with the myr-
iad of disease targets, not only hundreds
of different infections but also many can-
cers as well as autoimmune, inflamma-
tory, and allergic conditions.
Yet there are at least three ways in
which vaccine science differs from the
mainstream of modern immunology. The
first is that teams of scientists often have
to interact on a regular basis, either within
laboratories, between laboratories, or
among institutions and countries, to solve
the challenges of vaccine biology. There
are just too many unknowns when it
comes to antigens, adjuvants, and pro-
tective immune responses (Figure 1).
Nevertheless, on a more hopeful note as
emphasized here, many medical condi-
tions can now be addressed from the
focused perspective of vaccination.
The second difference from what im-
munologists are accustomed to is that
vaccine science involves humans, not
only mice. I am not referring to large-scale
clinical trials testing whether existing
practices and concepts are effective.322 Immunity 29, September 19, 2008 ª200Rather, we need to work out principles
that govern the regulation of the human
immune system in vivo and integrate this
research with other medical sciences
such as microbiology, genetics, and can-
cer biology. Basic research in humans is
much more demanding in terms of costs,
multiple regulations, and time constraints.
Along with our current successful re-
search enterprise, we now need to ex-
pand our research to study directly in pa-
tients the distinct pathogens and medical
conditions that threaten us.
The third difference is that vaccine sci-
ence involves discoveries that differ from
what most scientists are so good at,
which is to dissect disease-relevant
mechanisms. The other less followed re-
search path, which is imperative for vac-
cine science, is to identify basic principles
that direct immune responses and apply
these to ‘‘develop innovative solutions
that do better than nature.’’ It is important
to dissect immune function in model sys-
tems. But it is equally challenging to dis-
cover how to direct immunity to create
vaccines that guide the human immune
system. Dendritic cells, as key orchestra-
tors of these responses in vivo, should
help in the quest to bring new vaccines
into medicine.
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